The kinds of CAR-T cells included the following: CD19, CD20, CD22, CD30, CD33, LeY Antigen, BCMA, and natural killer group 2D (NKG2D) for hematological malignancies, and carcinoembryonic antigen (CEA), epidermal growth factor receptor (EGFR), GD2, IL13 receptor α2, epidermal growth factor receptor 2 (HER2), mesothelin, prostate specific membrane antigen (PSMA), and tumor-associated glycoprotein-72 (TAG72) for solid tumors. This evidence concerns the gene CD19 and hematologic disorder.